Short answer
ARDELYX, INC. (ARDX) filed its fiscal 2025 10-K annual report with the SEC on Feb 19, 2026. It reported revenue of $407M (+22.1% year over year) and net income of −$62M.
- Top risk flagged: Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue
FY2025 key financial metrics · XBRL
- Revenue
- $407M
- +22.1% YoY
- Net income
- −$62M
- −57.4% YoY
- Operating margin
- -10.1%
- −1.7 pp YoY
- EPS (diluted)
- −$0.26
- −52.9% YoY
- ROE
- -36.9%
- −14.3 pp YoY
- Operating cash flow
- −$42M
- +5.2% YoY
Source: XBRL data from the ARDELYX, INC. (ARDX) FY2025 10-K on SEC EDGAR. USD.
ARDELYX, INC. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Development and commercialization of innovative medicines focused on tenapanor-based therapies for gastrointestinal and kidney diseases
- New emphasis on Phase 3 trial initiation in January 2026 for tenapanor in chronic idiopathic constipation (CIC), targeting a new patient population of 34 million Americans
- Strategic shift: Navigating the 2025 Medicare Part D reimbursement change eliminating coverage for XPHOZAH, focusing on preserving patient access despite revenue impact
- Notable quantitative metric: Cash, cash equivalents, and short-term investments increased 5.8% to $264.7 million as of December 31, 2025, supporting ongoing operations and growth
- Significant IP advancement: Receipt of U.S. Patent No. 12,539,299 in January 2026 extending protection for tenapanor formulations in IBSRELA and XPHOZAH until 2042
Management Discussion & Analysis
- Total revenue $407.3M, up 22% YoY from $333.6M in 2024; product sales $377.8M, up 18% YoY from $319.2M
- Operating expenses $448.3M, up 24% YoY from $361.6M; cost of sales down 22% to $39.5M vs $50.6M; R&D up 37% to $71.5M; SG&A up 30% to $337.2M
- Best performing segment: IBSRELA sales $274.2M, up 73% YoY; worst: XPHOZAH sales $103.6M, down 36% YoY due to Medicare Part D reimbursement loss
- Cash, cash equivalents, and short-term investments $264.7M vs. $250.1M in 2024; no shares sold under ATM offerings in 2025; debt financing amended with $50M drawn in June 2025 plus $100M available through 2026
- Management outlook: ongoing Phase 3 trial for CIC indication with topline data in H2 2027; advancing next-generation NHE3 inhibitor program; key risk in payor mix and reimbursement changes impacting sales and GTN adjustments (30.2% in 2025 vs 25.6% prior year)
Risk Factors
- Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue
- Geopolitical/macro risk: Foreign price controls in Europe, Canada, Japan, China may limit IBSRELA and XPHOZAH pricing and reduce international revenue
- Operational risk: Dependence on third-party CMOs for manufacturing IBSRELA and XPHOZAH with single-source suppliers risks supply interruptions and regulatory non-compliance
- Competitive risk: Market acceptance and payer coverage pressures for IBSRELA and XPHOZAH amid existing and developing alternative therapies
- Financial risk: Accumulated deficit of $946.9M as of Dec 31, 2025, with continued losses risking cash flow sustainability and reliance on future fundraising
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.